Furthermore, a rapamycin phase I trial was conducted in recurrent glioma patients deficient in PTEN based on preclinical data where PTEN mutant/null tumors exhibited an enhanced susceptibility to mTOR inhibition [50–52]. This evidence concerns the gene PTEN and glioma.